Entecavir versus lamivudine for HBeAg positive and negative chronic hepatitis B
Open Access
- 30 September 2006
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 45 (3) , 457-460
- https://doi.org/10.1016/j.jhep.2006.06.012
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis BGastroenterology, 2006
- 85 Five years of sequential LAM TO LAM+ADV therapy suppresses HBV replication in most HBeAg-negative cirrhotics, preventing decompensation but not hepatocellular carcinomaJournal of Hepatology, 2006
- 45 Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(−) chronic hepatitis B patients (study ETV-027)Journal of Hepatology, 2006
- Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2006
- A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis BNew England Journal of Medicine, 2006
- Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis BNew England Journal of Medicine, 2005
- Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trialThe Lancet, 2005
- Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudineHepatology, 2004